CONSHOHOCKEN, Pa. - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has announced the completion of patient enrollment for its MAESTRO-NASH OUTCOMES trial, which evaluates resmetirom as a potential treatment for compensated nonalcoholic steatohepatitis (NASH) cirrhosis. This marks a significant step toward potentially providing the first approved medication for this high-risk patient group.
The MAESTRO-NASH OUTCOMES study is a Phase 3, double-blind, randomized, placebo-controlled trial involving 845 patients with compensated NASH cirrhosis. The trial exceeded its initial enrollment target and aims to measure the progression to liver decompensation events. Patients in the study have been randomized to receive either 80 mg of resmetirom or a matching placebo once daily, with the study duration expected to last two to three years to accrue the required number of clinical outcome events.
NASH is a leading cause of liver transplantation in the U.S., particularly among women, and represents an increasing burden on healthcare systems worldwide. The disease is associated with high rates of liver-related mortality, especially as patients progress to more advanced stages of liver fibrosis and cirrhosis. Madrigal's Chief Executive Officer, Bill Sibold, emphasized the urgent need for effective therapies to prevent progression to more severe complications, including the need for liver transplants.
The company's confidence in the trial is supported by positive 52-week data from a previous Phase 3 study, MAESTRO-NAFLD-1, which examined 180 patients with compensated NASH cirrhosis. Chief Medical Officer Becky Taub highlighted resmetirom's antifibrotic profile as a liver-directed THR-β agonist, which has shown promise in earlier trials.
Madrigal is also conducting other Phase 3 clinical trials, including the MAESTRO-NAFLD-1 (Safety) study, to evaluate the safety and tolerability of resmetirom. The primary results from the MAESTRO-NAFLD-1 trial were published in Nature Medicine in October 2023.
Resmetirom has already received accelerated approval for the treatment of NASH with moderate to advanced liver fibrosis based on earlier data. A positive outcome from the MAESTRO-NASH OUTCOMES trial is expected to support full approval of Rezdiffra for noncirrhotic NASH and could expand its indication to patients with compensated NASH cirrhosis.
This article is based on a press release statement from Madrigal Pharmaceuticals. The company is dedicated to long-term leadership in NASH research and development, aiming to shape the treatment paradigm for the disease over the coming decade.
In other recent news, Madrigal Pharmaceuticals reported encouraging results from its drug REZDIFFRA, showing improvements in health-related quality of life for patients with nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis. The drug is expected to generate revenue of $31.3 million for the third quarter of 2024, according to consensus estimates. Piper Sandler, maintaining its Overweight rating on Madrigal Pharmaceuticals, emphasized REZDIFFRA's strong competitive profile, highlighting the successful transition from Phase 2b to Phase 3 trials.
Madrigal has also announced the appointment of Dr. Michael R. Charlton, a renowned expert in NASH, as Senior Vice President of Clinical Development, strengthening its commitment to NASH research and innovation. The company is preparing for a potential European launch of REZDIFFRA in mid-2025, backed by a cash reserve of over $1 billion as of the second quarter of 2024. These are the recent developments in the company's ongoing efforts to improve treatment options for NASH patients.
InvestingPro Insights
Madrigal Pharmaceuticals' (NASDAQ:MDGL) recent milestone in its MAESTRO-NASH OUTCOMES trial aligns with its strong financial position and market performance. According to InvestingPro data, the company boasts a market capitalization of $4.66 billion, reflecting investor confidence in its NASH research pipeline.
Despite the company's current lack of profitability, with a negative P/E ratio of -9.12 over the last twelve months, Madrigal's focus on developing groundbreaking treatments for NASH has contributed to its impressive stock performance. InvestingPro Tips highlight that MDGL has delivered a high return over the last year, with a 63.02% price total return.
The company's solid financial foundation is evident from another InvestingPro Tip, which notes that Madrigal holds more cash than debt on its balance sheet. This financial stability is crucial for sustaining its extensive clinical trials and research efforts in the NASH treatment space.
For investors seeking a deeper understanding of Madrigal's potential, InvestingPro offers 11 additional tips, providing a comprehensive analysis of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.